首页> 外文期刊>Endocrine journal >Clinical Course of Patients with Nonclassical 21-hydroxylase Deficiency (21-OHD) Diagnosed in Infancy and Childhood
【24h】

Clinical Course of Patients with Nonclassical 21-hydroxylase Deficiency (21-OHD) Diagnosed in Infancy and Childhood

机译:患有非典型21-羟化酶缺乏症(21-OHD)的婴儿和儿童被诊断为临床病程

获取原文
获取原文并翻译 | 示例
       

摘要

We report four cases of nonclassical 21-hydroxylase deficiency (21-OHD) diagnosed in neonate or early childhood. The four patients comprised a 6-year, 5-month-old male (case 1); a 3-year, 10-month-old female (case 2); a 13-year, 11-month-old female (case 3) and a 17-year, 1-month-old male (case 4). Cases 3 and 4 were siblings. None had any signs of virilization or salt wasting at birth. 21-OHD was diagnosed using ACTH loading test and other adrenal steroid evaluations. Mutations of the CYP21 gene were detected in all patients. Three patients (cases 1, 3 and 4) had positive results in neonatal mass screening. Cases 1 and 2 showed no apparent signs of virilizaton and were observed without conventional treatment. In cases 3 and 4, because of increased growth velocity and accelerated bone maturation, hydrocortisone administration was initiated from their late infantile period. In spite of hydrocortisone treatment, in case 4, the final height of 159.7 cm was less than his predicted final height. Besides he revealed adrenal insufficiency at the age of 9 years and 2 months old caused by viral infection. Hydrocortisone supplementation therapy may cause adrenal insufficiency in nonclassical patients due to suppression of the hypothalamus-pituitary-adrenal axis. The clinical courses in these cases were various, and it was difficult to predict the appearance of any symptoms of virilization. Careful observation is necessary.
机译:我们报告了四例在新生儿或儿童早期诊断出的非经典21-羟化酶缺乏症(21-OHD)。 4例患者为6岁5个月大的男性(病例1)。 3岁10个月大的女性(案例2);一名13岁11个月大的女性(案例3)和一名17岁1个月大的男性(案例4)。病例3和4是兄弟姐妹。没有人出生时有任何变态或盐分流失的迹象。使用ACTH负荷测试和其他肾上腺类固醇评估诊断为21-OHD。在所有患者中均检测到CYP21基因的突变。 3例患者(1、3和4例)在新生儿肿块筛查中呈阳性结果。病例1和2没有明显的软化迹象,没有进行常规治疗就可以观察到。在病例3和4中,由于生长速度加快和骨骼成熟加快,因此从婴儿后期开始就开始氢化可的松给药。尽管进行了氢化可的松治疗,在情况4中,最终高度159.7 cm仍低于他的预期最终高度。此外,他还发现了由病毒感染引起的9岁零2个月大的肾上腺功能不全。氢化可的松补充疗法可能会由于抑制下丘脑-垂体-肾上腺轴而引起非经典患者的肾上腺功能不全。这些情况下的临床过程是多种多样的,并且难以预测任何病毒化症状的出现。仔细观察是必要的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号